Abstract
Subcutaneous interferon beta 1a (IFN β 1a) has been shown to reduce relapse rates in patients with relapsing-remitting
multiple sclerosis. We report the occurrence of severe necrotizing cutaneous reactions in a 19-year-old girl. She self
injected IFN β 1a three times a week on the abdomen and both thighs. Treatment was initially well tolerated, but she
described erythematous patches and local pain at the injection sites recently. The areas on the abdomen became
violaceous with necrotic ulcers. Her therapy was changed to 0.5 mg fingolimod. The lesions began to improve and
cicatrize after several weeks with postinflammatory hyperpigmentation. Early recognition of severe local adverse
reactions and correction of the injection technique is important.
Keywords
References
- 1. PRISMS (Prevention of Relapses and Disability by Interferon betala Subcutaneously in Multiple sclerosis) Study Group. Randomized double-blind placebo-controlled study of interferon beta-la in relapsing-remitting multiple sclerosis. Lancet 1998;352:1498-504.
- 2. Elgart GW, Sheremata W, Ahn YS. Cutaneous reactions to recombinant human interferon beta 1b: The clinical and histologic spectrum. J Am Acad Dermatol 1997;37:5538.
- 3. Lebrun C, Bertagna M, Cohen M. Cutanous side effects of immunomodulators in MS. Int MS J 2011;17:88-94.
- 4. Beer K, Müller M, Hew-Winzeler AM, Bont A, Maire P, You X, et al. The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: An observational study. BMC Neurol 2011;11:144.
- 5. Sheremata WA, Taylor JR, Elgart GW. Severe necrotizing cutaneous lesions complicating treatment with interferon beta-1b. N Engl J Med 1995;332:1584.
Abstract
References
- 1. PRISMS (Prevention of Relapses and Disability by Interferon betala Subcutaneously in Multiple sclerosis) Study Group. Randomized double-blind placebo-controlled study of interferon beta-la in relapsing-remitting multiple sclerosis. Lancet 1998;352:1498-504.
- 2. Elgart GW, Sheremata W, Ahn YS. Cutaneous reactions to recombinant human interferon beta 1b: The clinical and histologic spectrum. J Am Acad Dermatol 1997;37:5538.
- 3. Lebrun C, Bertagna M, Cohen M. Cutanous side effects of immunomodulators in MS. Int MS J 2011;17:88-94.
- 4. Beer K, Müller M, Hew-Winzeler AM, Bont A, Maire P, You X, et al. The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: An observational study. BMC Neurol 2011;11:144.
- 5. Sheremata WA, Taylor JR, Elgart GW. Severe necrotizing cutaneous lesions complicating treatment with interferon beta-1b. N Engl J Med 1995;332:1584.
Details
| Primary Language | English |
|---|---|
| Subjects | Internal Diseases |
| Journal Section | Case Report |
| Authors | |
| Publication Date | December 30, 2018 |
| Submission Date | October 6, 2017 |
| Published in Issue | Year 2018 Volume: 12 Issue: 4 |
Cited By
The publication language of Turkish Journal of Pediatric Disease is English.
Manuscripts submitted to the Turkish Journal of Pediatric Disease will go through a double-blind peer-review process. Each submission will be reviewed by at least two external, independent peer reviewers who are experts in the field, in order to ensure an unbiased evaluation process. The editorial board will invite an external and independent editor to manage the evaluation processes of manuscripts submitted by editors or by the editorial board members of the journal. The Editor in Chief is the final authority in the decision-making process for all submissions. Articles accepted for publication in the Turkish Journal of Pediatrics are put in the order of publication, with at least 6 original articles in each issue, taking into account the acceptance dates. If the articles sent to the reviewers for evaluation are assessed as a senior for publication by the reviewers, the section editor and the editor considering all aspects (originality, high scientific quality and citation potential), it receives publication priority in addition to the articles assigned for the next issue.
The aim of the Turkish Journal of Pediatrics is to publish high-quality original research articles that will contribute to the international literature in the field of general pediatric health and diseases and its sub-branches. It also publishes editorial opinions, letters to the editor, reviews, case reports, book reviews, comments on previously published articles, meeting and conference proceedings, announcements, and biography. In addition to the field of child health and diseases, the journal also includes articles prepared in fields such as surgery, dentistry, public health, nutrition and dietetics, social services, human genetics, basic sciences, psychology, psychiatry, educational sciences, sociology and nursing, provided that they are related to this field. can be published.